Zurcher Kantonalbank Zurich Cantonalbank Purchases 27,436 Shares of Novavax, Inc. (NASDAQ:NVAX)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Novavax, Inc. (NASDAQ:NVAX) by 45.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,739 shares of the biopharmaceutical company’s stock after purchasing an additional 27,436 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Novavax were worth $421,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Novavax by 9.3% in the third quarter. Vanguard Group Inc. now owns 11,551,476 shares of the biopharmaceutical company’s stock valued at $83,633,000 after buying an additional 978,873 shares during the period. TSP Capital Management Group LLC increased its position in Novavax by 15.0% in the 4th quarter. TSP Capital Management Group LLC now owns 1,111,700 shares of the biopharmaceutical company’s stock valued at $5,336,000 after acquiring an additional 145,350 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Novavax by 7.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 703,350 shares of the biopharmaceutical company’s stock valued at $5,092,000 after acquiring an additional 51,274 shares during the last quarter. Rock Springs Capital Management LP lifted its holdings in shares of Novavax by 20.7% during the third quarter. Rock Springs Capital Management LP now owns 647,700 shares of the biopharmaceutical company’s stock worth $4,689,000 after purchasing an additional 111,000 shares during the period. Finally, Barclays PLC grew its stake in shares of Novavax by 2.3% in the third quarter. Barclays PLC now owns 553,790 shares of the biopharmaceutical company’s stock worth $4,011,000 after purchasing an additional 12,235 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

Novavax Price Performance

Shares of NVAX stock opened at $4.93 on Friday. The stock has a market capitalization of $692.17 million, a PE ratio of -0.89 and a beta of 1.63. The business’s 50 day simple moving average is $4.71 and its 200 day simple moving average is $5.03. Novavax, Inc. has a one year low of $3.53 and a one year high of $11.36.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.95). The firm had revenue of $291.34 million for the quarter, compared to the consensus estimate of $310.96 million. During the same quarter in the prior year, the company posted ($2.28) earnings per share. The business’s revenue was down 18.5% on a year-over-year basis. As a group, research analysts expect that Novavax, Inc. will post -0.82 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright lowered their target price on Novavax from $35.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, March 1st.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.